In this podcast, we feature an article that examines the effect of COVID-19 on drug development, clinical trials, regulatory review, and new drug approvals.  For the text version of this article visit dcatvci.org.

Key topics: (see Chapter Markers)

• Drug development and regulatory review
• FDA’s perspective
• New drug approvals thus far in 2020
• Clinical trials and COVID-19: where the impact resides
• Companies adjust clinical-trial research strategies

Sponsor: CordenPharma